Bausch Health Companies Inc. (BHC) |
| 5.72 0.12 (2.14%) 04-13 16:00 |
| Open: | 5.545 |
| High: | 5.75 |
| Low: | 5.54 |
| Volume: | 719,020 |
| Market Cap: | 2,120(M) |
| PE Ratio: | 13.62 |
| Exchange: | New York Stock Exchange |
| Industry: | Drug Manufacturers - Specialty & Generic |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 6.72 |
| Resistance 1: | 5.75 |
| Pivot price: | 5.29 |
| Support 1: | 5.24 |
| Support 2: | 4.93 |
| 52w High: | 8.69 |
| 52w Low: | 4.28 |
Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
| EPS | 0.420 |
| Book Value | -1.500 |
| PEG Ratio | 0.00 |
| Gross Profit | 19.565 |
| Profit Margin (%) | 1.53 |
| Operating Margin (%) | 25.79 |
| Return on Assets (ttm) | 5.2 |
| Return on Equity (ttm) | 436.4 |
Mon, 13 Apr 2026
Bausch Health rises after $300M worth insider purchase (update) - MSN
Wed, 08 Apr 2026
Bausch Health (NYSE: BHC) outlines 2026 virtual meeting, board slate and say-on-pay vote - Stock Titan
Thu, 02 Apr 2026
[Form 4] Bausch Health Companies Inc. Insider Trading Activity - Stock Titan
Tue, 31 Mar 2026
Bausch Health to Announce First Quarter 2026 Results on April 29, 2026 - Yahoo Finance
Tue, 31 Mar 2026
Bausch Health to Announce First Quarter 2026 Results on April 29, 2026 - Quantisnow
Thu, 26 Mar 2026
Bausch Health Announces Ortho Dermatologics 2026 ASPIRE HIGHER Scholarship Program - PR Newswire
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |